As the first-generation ALK inhibitor, crizotinib showed superior efficacy compared to platinum–pemetrexed chemotherapy in NSCLC with ALK, MET and ROS1 alterations (120). This evidence concerns the gene ALK and non-small cell lung carcinoma.